CAN RIVAROXABAN BECOME COST SAVING COMPARED WITH VITAMIN K ANTAGONISTS IN THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN FRANCE? (submitted in 2019)